Glioblastoma is an inevitably lethal intrinsic brain tumor thought to derive from neuroglial progenitor cells that affects more than 3/100,000 individuals per year worldwide.1,2 The standard of care, neurosurgical resection as safely feasible followed by radiotherapy with concomitant and subsequent maintenance temozolomide chemotherapy (TMZ/RT ! TMZ) results in a median survival of 16 months in clinical trial populations.3 All pharmacologicaland immunotherapeutic approaches to improve outcome beyond this standard of care have failed.4